# Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer

> **NCT00532285** · PHASE2 · TERMINATED · sponsor: **National Cancer Center, Korea** · enrollment: 44 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Paclitaxel/Gemcitabine

## Key facts

- **NCT ID:** NCT00532285
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2006-04
- **Final completion:** 2009-08
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** terminated
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532285, "Primary Paclitaxel Plus Gemcitabine in Patients With Stage II and III Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00532285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*